Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins

Conclusion  IVIG represents a promising immunoregulatory agent which has the ability to control autoimmune disorders without subsequent predisposition to infectious complications. However, it is extremely expensive: the approximate average wholesale price is U.S. $1,800 per dose for a 70-kg patient. Further studies and controlled clinical trials will be necessary to prove the efficacy of this therapy for specific autoimmune disorders.